Lexicon Pharmaceuticals | LXRX - Trade Creditors


Lexicon Pharmaceuticals reported $3M in Trade Creditors for its fiscal quarter ending in March of 2026.





Trade Creditors Change Date
Abbott USD 4.24B 117M Dec/2025
Acadia Pharmaceuticals USD 12.25M 1.34M Mar/2026
Agios Pharmaceuticals USD 13.75M 4.61M Mar/2026
Akebia Therapeutics USD 8.39M 12.8M Mar/2026
Alnylam Pharmaceuticals USD 126.63M 10.91M Mar/2026
AstraZeneca USD 22.51B 2.78B Mar/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Coherus Biosciences USD 9.91M 14.98M Dec/2025
Eli Lilly USD 5.03B 350M Mar/2026
Esperion Therapeutics USD 68.41M 3.34M Mar/2026
Halozyme Therapeutics USD 14.1M 6.8M Mar/2026
Illumina USD 218M 22M Mar/2026
Insmed USD 73.38M 6.53M Mar/2026
Ironwood Pharmaceuticals USD 3.24M 339K Mar/2026
J&J USD 10.46B 1.53B Mar/2026
Lexicon Pharmaceuticals USD 3M 87K Mar/2026
MacroGenics USD 4.29M 500K Mar/2026
MannKind USD 16.14M 7.11M Mar/2026
Merck USD 3.86B 541M Mar/2026
Moderna USD 161M 156M Mar/2026
Novartis USD 4.32B 134M Mar/2026
PTC Therapeutics USD 25.48M 20M Mar/2026
Puma Biotechnology USD 6.39M 962K Sep/2025
Sarepta Therapeutics USD 70.38M 210.46M Mar/2026
Thermo Fisher Scientific USD 3.34B 278M Mar/2026
Ultragenyx Pharmaceutical USD 42M 11M Mar/2026
United Therapeutics USD 498.3M 491.2M Mar/2026
Vanda Pharmaceuticals USD 39.09M 33.28M Dec/2024